ArticleDiagnostic and interventional radiology (Ankara, Turkey)2026
Single-center retrospective comparative study of 40-120 μm versus 100-300 μm trisacryl gelatin microspheres as the main embolic agents for prostatic artery embolization.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the safety and efficacy of trisacryl gelatin microspheres (TGM) with diameters of 40-120 μm (TGM 40-120) vs. 100-300 μm (TGM 100-300) as the primary embolic agents for prostatic artery (PA) embolization (PAE).
methodsThis single-center retrospective comparative study included patients with symptomatic benign prostatic hyperplasia treated with PAE using TGM 40-120 (group A) or TGM 100-300 (group B) over a two-year period. Evaluation included International Prostate Symptom Score (IPSS), quality of life score (QoL), prostatic volume (PV), post-void residual (PVR), and percentage of prostatic infarction (pPI) measured by contrast-enhanced ultrasound. Clinical success was defined as post-PAE reduction of IPSS ≤ 15 points with a decrease of at least 25% from the baseline, QoL score ≤ 3 points or a decrease of at least 1 point from baseline, and successful bladder catheter removal (for catheter-dependent patients). Adverse events were recorded and graded using the modified CIRSE classification system for complication reporting.
resultsMost baseline characteristics did not differ significantly between group A (n = 21) and group B (n = 31). At 3 months post-PAE, there were no statistically significant differences between groups in improvement of IPSS (group A: 49.5 ± 26.1%, group B: 51.8 ± 23.3%,
conclusionCompared with TGM 100-300, PAE with TGM 40-120 appears to provide similar clinical benefit but results in significantly higher pPI and greater mid-term prostate shrinkage. Ischemic complications may be more frequent and more severe with the smaller microspheres. CLINICAL SIGNIFICANCE: This is the first systematic comparison between the smallest and the second smallest commercially available TGM sizes in the clinical context of PAE. These findings may help guide ongoing research to identify the most appropriate embolic material for PAE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.